Trial intelligence / Profile preview

Acarbose effects on incretin secretion in newly diagnosed type 2 diabetes

ChiCTR-TRC-14004260Phase 4Completed

Sponsor
Guangdong Provincial People's Hospital
Start
Jan 2009
Modality
Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
Countries
1
01

Overview

Phase 4, open-label trial of acarbose in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: GLP-1, GIP and 1 more. Started Jan 2009; status: completed.

02

Drugs

acarbose
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on ChiCTR-TRC-14004260.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-TRC-14004260.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call